<DOC>
	<DOCNO>NCT02255734</DOCNO>
	<brief_summary>Bioequivalence two formulation Acyclovir ( Acyclovir Lyophilized I.V . infusion 250mg ) Intravenous Infusion Healthy Volunteers .</brief_summary>
	<brief_title>Bioequivalence Two Formulations Acyclovir</brief_title>
	<detailed_description />
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Healthy adult male female subject 20 45 year age Body weight within 80 120 percentage ideal body weight high equal 50 kg male subject 45 kg female subject Acceptable medical history physical examination include particular clinically significant abnormality xray ECG result within six month prior period I dosing.no particular clinical significance general disease history within two month prior period I dose Acceptable vital sign within normal limit consider investigator physician clinical significance screening , include pulse rate , blood pressure body temperature Acceptable clinical chemistry determination within normal limit consider investigator physician clinical significance within two month prior Period I dose , include AST , ALT , GT , alkaline phosphatase , total bilirubin , albumin , glucose , BUN , uric acid , creatinine , total cholesterol triglyceride Acceptable hematology within normal range consider investigator physician clinical significance within two month prior Period I dose , include hemoglobin , hematocrit , red blood cell count , white blood cell count differential platelet Acceptable urinalysis within normal limit consider investigator physician clinical significance within two month prior Period I dose , include pH , blood , glucose , ketone , bilirubin protein Female subject childbearing potential practicing acceptable method birth control duration study judge investigator surgically sterile bilateral tubal ligation , bilateral oophorectomy hysterectomy perform subject Have sign write informed consent participate study A clinically significant disorder involve cardiovascular , respiratory , hepatic , renal , gastrointestinal , immunologic , hematologic , endocrine neurologic system psychiatric disease determine clinical investigator A clinically significant illness surgery within four week prior Period I dose determined investigator History gastrointestinal obstruction , inflammatory bowel disease , gallbladder disease , pancreas disorder last two year history gastrointestinal tract surgery last five year History kidney disease urination problem last two year deem investigator clinically significant Known suspect history drug abuse within lifetime judge investigator History alcohol addiction abuse within last five year judge investigator History allergic response acyclovir , valacyclovir relate drug Evidence chronic acute infectious disease Female subject demonstrate positive urine pregnancy screen prior study Female subject currently breastfeed Taking drug know induce inhibit hepatic drug metabolism within four week prior Period I dose . Examples inducer include . piperidines , carbamazepine , dexamethasone rifampin . Examples inhibitor include : cimetidine , diphenhydramine , fluvastatin , methadone ranitidine Taking prescription medication within four week nonprescription medication exclude flu vaccination within two week prior Period I dose</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Volunteers</keyword>
</DOC>